Chronic lung allograft dysfunction (CLAD) is still the principal long-term cause of mortality after lung transplant. Animal studies and small case series have proposed pirfenidone, a potent antifibrotic agent registered for idiopathic pulmonary fibrosis (IPF), for treatment of CLAD. The aim of this study was to evaluate the safety profile and potential efficacy of pirfenidone in patients with CLAD.
Bennett, D., Lanzarone, N., Fossi, A., Perillo, F., De Vita, E., Luzzi, L., et al. (2020). Pirfenidone in chronic lung allograft dysfunction: a single cohort study. PANMINERVA MEDICA [10.23736/S0031-0808.19.03840-0].
Pirfenidone in chronic lung allograft dysfunction: a single cohort study
Bennett, David;Lanzarone, Nicola;De Vita, Elda;Luzzi, Luca;Paladini, Piero;Bargagli, Elena;Sestini, Piersante;Rottoli, Paola
2020-01-01
Abstract
Chronic lung allograft dysfunction (CLAD) is still the principal long-term cause of mortality after lung transplant. Animal studies and small case series have proposed pirfenidone, a potent antifibrotic agent registered for idiopathic pulmonary fibrosis (IPF), for treatment of CLAD. The aim of this study was to evaluate the safety profile and potential efficacy of pirfenidone in patients with CLAD.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1104997
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo